Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124710 | 0.93 | PKM (0.50) | EPHX2MAPTHSD17B10PKMKMT2A | |
| SCHEMBL4119727 | 0.93 | EPHX2 (0.55) | EPHX2MAPTPKMKMT2ACNR1 | |
| SCHEMBL4112177 | 0.90 | EPHX2 (0.59) | EPHX2MAPTKMT2ACNR1CCR3 | |
| SCHEMBL4111553 | 0.88 | CASR (0.53) | EPHX2MAPTPKMKMT2ACCR3 | |
| SCHEMBL4118060 | 0.87 | EPHX2 (0.59) | EPHX2KMT2ACCR3 | |
| SCHEMBL4116411 | 0.86 | CNR1 (0.54) | EPHX2MAPTKMT2ACNR1CCR3 | |
| SCHEMBL4106984 | 0.86 | EPHX2 (0.58) | EPHX2KMT2ACCR3 | |
| SCHEMBL4118371 | 0.86 | EPHX2 (0.54) | EPHX2MAPTKMT2ACNR1CCR3 | |
| SCHEMBL4113123 | 0.86 | CNR1 (0.60) | EPHX2MAPTKMT2ACNR1CCR3 | |
| SCHEMBL4107145 | 0.86 | CNR1 (0.60) | EPHX2MAPTKMT2ACNR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | EPHX2 1614/4885MAPT 1996/4885HSD17B10 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.